Vacc-4x phase IIB study accepted as a poster at AIDS conference in Bangkok
Oslo, 01.08.2011 - An abstract of Bionor Pharma's Vacc-4x phase IIB study has been accepted as a poster at the AIDS Vaccine 2011 conference in Bangkok 12-15 September.
Clinical and preliminary immunological data from the study together with new data on the long term follow-up of patients (up to one year after the study end) will be presented under the title: "A Phase IIB, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in HIV-1-infected Patients".
The presentation at the AIDS Vaccine 2011 meeting will be a follow-up from the data presented at the International AIDS Society (IAS) conference in Rome 17-20 July. Collectively, the data presented at both conferences will form a foundation upon which new clinical collaborations and partnering opportunities for Vacc-4x can be explored.